Advertisement
Canada markets close in 4 hours 40 minutes

  • S&P/TSX

    21,925.10
    +39.72 (+0.18%)
     

  • S&P 500

    5,098.92
    +50.50 (+1.00%)
     

  • DOW

    38,174.08
    +88.28 (+0.23%)
     

  • CAD/USD

    0.7304
    -0.0019 (-0.26%)
     

  • CRUDE OIL

    83.65
    +0.08 (+0.10%)
     

  • Bitcoin CAD

    87,170.99
    +295.30 (+0.34%)
     

  • CMC Crypto 200

    1,330.32
    -66.21 (-4.75%)
     

  • GOLD FUTURES

    2,345.30
    +2.80 (+0.12%)
     

  • RUSSELL 2000

    1,999.87
    +18.75 (+0.95%)
     

  • 10-Yr Bond

    4.6630
    -0.0430 (-0.91%)
     

  • NASDAQ

    15,926.68
    +314.92 (+2.02%)
     

  • VOLATILITY

    15.34
    -0.03 (-0.20%)
     

  • FTSE

    8,140.14
    +61.28 (+0.76%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica

Zacks Equity Research
Updated

AbbVie Inc. ABBV announced the submission of a supplemental New Drug Application (sNDA) for its blood cancer drug Imbruvica (ibrutinib) in the U.S.
 

AbbVie is looking for a label expansion of Imbruvica to include the treatment of marginal zone lymphoma (MZL). MZL is a slow-growing form of non-Hodgkin's lymphoma.
 

Imbruvica is currently approved in the U.S. for the treatment of patients with MCL or CLL who have received at least one previous therapy and for CLL patients with deletion 17p. It is also approved for the treatment of Waldenstrom's macroglobulinemia. This is the fifth time that AbbVie has filed an sNDA for Imbruvica.
 

Pharmacyclics LLC, a subsidiary of AbbVie, markets Imbruvica under a partnership with Johnson & Johnson’s JNJ Janssen Biotech, Inc.
 

ADVERTISEMENT

The sNDA was based on data from a multi-center, open-label phase II PCYC-1121-CA trial assessing Imbruvica as a single-agent treatment for MZL. The study enrolled 63 previously treated patients with MZL. Patients were received once-daily oral administration of ibrutinib alone. The primary endpoint of the overall response rate as assessed by an Independent Review Committee was met.
 

We remind investors that in Apr 2013, the FDA had granted Breakthrough Therapy designation to ibrutinib for the treatment of CLL/small lymphocytic lymphoma patients, with a deletion of chromosome 17p. Earlier this year, the regulatory agency granted Breakthrough Therapy designation to ibrutinib for the treatment of mantle cell lymphoma patients as monotherapy. The FDA granted also granted Breakthrough Therapy status to the candidate for the treatment of patients suffering from Waldenström's macroglobulinemia as monotherapy. We expect investor focus to remain on the further development of ibrutinib.
 

AbbVie expects Imbruvica peak sales of over $7 billion and revenues of about $5 billion in 2020. We believe Imbruvica has multi-billion dollar potential and AbbVie is working on expanding Imbruvica’s label to include solid tumors and autoimmune diseases. The company sees Imbruvica as a “pipeline in a molecule” given that the treatment is presently in several company-sponsored studies. A registrational study for graft-versus-host disease is underway, with data expected later this year or early 2017.
 

We remind investors that Imbruvica was added to AbbVie’s portfolio following its Pharmacyclics acquisition in May 2015.

ABBVIE INC Price

 

ABBVIE INC Price | ABBVIE INC Quote

Zacks Rank & Key Picks

AbbVie currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. ANIK and ANI Pharmaceuticals, Inc. ANIP. Both the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.


Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 20.3% year to date.

ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, over the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 48.3% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
 
ABBVIE INC (ABBV): Free Stock Analysis Report
 
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research